23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC 2025)

The 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC 2025) is dedicated to exploring insulin resistance, obesity, diabetes, and related conditions such as kidney disease, cardiovascular disease, and fatty liver morbidity.

Topics

• The effect of lipotoxicity and the pathophysiology of cardiovascular disease (CVD)
• The relationship between diabetes, obesity, and congestive heart failure
• The roles of diabetes in the development of micro and macrovascular conditions: kidney disease, retinopathy, neuropathy, CVD, and strokes
• The role of obesity in the development of cardiometabolic conditions
• The role of incretins in the management of diabetes, obesity, and related complications
• Comprehensive management of diabetes by addressing obesity, hypertension, dyslipidemia, and hyperglycemia
• The role of SGLT2 inhibitors and GLP1 receptor agonists for primary prevention of cardiovascular morbidity and mortality in patients with type 2 diabetes (T2D)
• Evidence supporting the use of SGLT2 inhibitors and GLP1 receptor agonists to reduce cardiovascular morbidity and mortality in patients with T2D and established CVD
• Fatty liver disease and its relationship to diabetes and CVD
• The role of PCSK9 inhibitors in preventing cardiovascular morbidity in people with established atherosclerotic cardiovascular disease (ASCVD)
• The impact on clinical practice of recent CVD, congestive heart failure (CHF), and chronic kidney disease (CKD) outcome trials
• The pathogenesis of liver and muscle insulin resistance, the role of adipose tissue, and mitochondria in hyperglycemia and ASCVD
• Best practices for the prevention and management of CHF
• The impact on clinical practice of lipid cardiovascular outcome trials, including IMPROVE-IT, FOURIER, REDUCE-IT, and ODYSSEY-Outcomes
• The role of coagulation and new anticoagulation agents in the prevention of CVD and cerebrovascular accidents (CVA)
• The cardiorenal syndrome
• Reducing morbidity and mortality by matching the correct medications to appropriate patients

Who Should Attend

• Endocrinologists
• Cardiologists
• Oncologists
• Gastroenterologists
• Diabetologists
• Internists
• Pediatricians
• OBGYNs
• Nurse practitioners
• Dietitians
• Pharmacists
• Other healthcare professionals